The effect of vitamin D replacement on spinal inhibitory pathways in women with chronic widespread pain

•Central pain sensitization accompanies chronic widespread pain.•Cutenous silent period (CSP) is an objective measure of central sensitization.•Vitamin D replacement improves pain and quality of life in chronic widespread pain.•Vitamin D replacement does not change CSP parameters. Vitamin D replacem...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of steroid biochemistry and molecular biology 2020-02, Vol.196, p.105488-105488, Article 105488
Hauptverfasser: Kenis-Coskun, Ozge, Giray, Esra, Gunduz, Osman Hakan, Akyuz, Gulseren
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•Central pain sensitization accompanies chronic widespread pain.•Cutenous silent period (CSP) is an objective measure of central sensitization.•Vitamin D replacement improves pain and quality of life in chronic widespread pain.•Vitamin D replacement does not change CSP parameters. Vitamin D replacement helps in pain reduction in patients with chronic widespread pain (CWP). But the current literature lack studies that investigate its mechanism. Cutaneous silent period (CSP) is the electrophysiologic analog of the spinal inhibitory pathways and an objective method to document their involvement. This study aims to show if vitamin D replacement has an effect on the spinal inhibitory pathways through CSP parameters. Female patients who have CWP with vitamin D deficiency were included. Patients received an 8-week replacement therapy of vitamin D. Patients’ pain were evaluated using the visual analog scale (VAS) and Leeds assessment of neuropathic symptoms and signs pain scale (LANSS). Quality of life with Nottingham Health Profile (NHP) and CSP parameters were also recorded before and after treatment. A total of 51 patients were included in the final analyses. The mean age of the patients was 44.3 ± 12.7 (minimum 18-maximum 65). Mean symptom duration was 13.1 ± 6.7 (minimum3-maximum 24) months. Patients' mean BMI was 21.6 ± 3.9 (minimum 18.0 maximum 29.1). Patients' median VAS and LANSS scores decreased significantly (p 
ISSN:0960-0760
1879-1220
DOI:10.1016/j.jsbmb.2019.105488